Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people...
33 KB (3,133 words) - 06:31, 11 November 2024
neuroprotection. The drugs clopidogrel (Plavix), prasugrel (Efient, Effient), ticagrelor (Brilinta), and cangrelor (Kengreal) bind to this receptor and are marketed...
10 KB (992 words) - 18:32, 10 December 2023
in-vivo to inhibit the P2Y12 receptor. On the other hand, novel drugs like ticagrelor (Brilinta®) and cangrelor (Kengrexal®) are non-thienopyridines and reversibly...
46 KB (5,282 words) - 08:16, 30 March 2024
of aspirin plus an ADP/P2Y inhibitor (such as clopidogrel, prasugrel, ticagrelor, or another) is used to obtain greater effectiveness than with either...
18 KB (1,752 words) - 10:58, 11 August 2024
trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta...
4 KB (200 words) - 00:21, 29 January 2023
order to avoid confusion with the blood-thinning medication Brilinta (ticagrelor). Other brand names include Torvox, Vantaxa, Voxigain, and Trivoxetin...
56 KB (4,814 words) - 23:18, 21 November 2024
Beraprost B01AC21 Treprostinil B01AC22 Prasugrel B01AC23 Cilostazol B01AC24 Ticagrelor B01AC25 Cangrelor B01AC26 Vorapaxar B01AC27 Selexipag B01AC28 Limaprost...
3 KB (346 words) - 19:19, 12 March 2024
medications: cisapride, pimozide, astemizole, terfenadine, ergotamine, ticagrelor, ranolazine or dihydroergotamine is not recommended. It should not be...
29 KB (2,711 words) - 14:43, 22 October 2024
advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited. It was patented in 1973 and approved for medical...
18 KB (1,724 words) - 08:54, 9 September 2024
indefinitely, as well as another antiplatelet agent such as clopidogrel or ticagrelor ("dual antiplatelet therapy" or DAPT) for up to twelve months. If someone...
129 KB (13,821 words) - 06:58, 18 November 2024
assessing cangrelor administration in conjunction with either prasugrel or ticagrelor. Cangrelor been approved for adults undergoing percutaneous coronary intervention...
15 KB (1,150 words) - 05:23, 3 March 2024
with presumed ACS are typically treated with aspirin, clopidogrel or ticagrelor, nitroglycerin, and, if the chest discomfort persists, morphine. Other...
31 KB (3,363 words) - 04:50, 22 October 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
280 KB (29,090 words) - 06:24, 21 November 2024
Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran...
56 KB (5,566 words) - 13:30, 2 November 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
201 KB (20,134 words) - 05:14, 22 November 2024
Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran...
42 KB (3,486 words) - 00:32, 30 September 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
20 KB (2,022 words) - 09:45, 19 November 2024
Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran...
79 KB (6,428 words) - 19:45, 22 November 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
32 KB (3,346 words) - 08:35, 21 September 2024
Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran...
31 KB (2,632 words) - 22:56, 26 October 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
31 KB (2,798 words) - 23:42, 18 October 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
26 KB (2,467 words) - 13:46, 2 November 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
32 KB (3,305 words) - 17:28, 19 November 2024
Anti-platelet agents include aspirin, dipyridamole, ticlopidine, clopidogrel, ticagrelor and prasugrel; the parenteral glycoprotein IIb/IIIa inhibitors are used...
64 KB (6,553 words) - 02:03, 21 November 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
41 KB (3,770 words) - 11:25, 22 November 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
54 KB (5,329 words) - 05:19, 17 November 2024
Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran...
31 KB (2,777 words) - 08:32, 19 October 2024
Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran...
92 KB (8,503 words) - 20:58, 17 November 2024
Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran...
42 KB (3,798 words) - 13:29, 20 November 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
38 KB (4,040 words) - 22:00, 12 October 2024